A1C Almanac

Main Page

PCOS as “Diabetes of the Ovaries” and the Metabolic Lens on a Reproductive Syndrome

Posted

by

dr Karunia Valeriani Japar

Table of Contents
Category:

Introduction

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age, with a global prevalence estimated at 8–13% depending on the diagnostic criteria used. It is classically defined by the presence of oligo‑ or anovulation, clinical and/or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasonography, after exclusion of secondary causes. Although historically conceptualized as a gynecologic condition, PCOS is now widely acknowledged as a complex neuroendocrine and metabolic disorder with reproductive, metabolic, and psychological dimensions that evolve across the life course.

Beyond menstrual irregularities and infertility, women with PCOS frequently exhibit insulin resistance, central adiposity, atherogenic dyslipidemia, and features of the metabolic syndrome, even when matched for body mass index with women without PCOS. Insulin resistance is observed in both obese and lean PCOS phenotypes, suggesting an intrinsic defect in insulin signalling that is amplified by excess adiposity. Epidemiological studies consistently demonstrate that women with PCOS have a substantially higher prevalence of impaired glucose tolerance and a two‑ to four‑fold increased risk of developing type 2 diabetes compared with weight‑matched controls, particularly when obesity and other components of metabolic syndrome coexist. These findings underpin the recognition of PCOS as a female‑specific cardiometabolic risk state associated with increased long‑term burden of type 2 diabetes, non‑alcoholic fatty liver disease, and cardiovascular disease.

Against this background, the provocative metaphor of PCOS as “diabetes of the ovaries” has gained traction in both scientific discourse and public health communication to capture the central role of insulin resistance and hyperinsulinemia in driving ovarian dysfunction. The term emphasizes that the ovary can be considered an early target organ of systemic metabolic dysregulation, in which hyperinsulinemia acts synergistically with gonadotropins to promote androgen excess and follicular arrest. However, this framing also risks oversimplifying a heterogeneous syndrome and may inadvertently pathologize all women with PCOS as being on an inevitable trajectory toward diabetes and cardiovascular disease. In this article, we critically examine the validity, clinical utility, and limitations of the “diabetes of the ovaries” metaphor, and explore how reframing PCOS through a metabolic and longevity‑oriented lens can inform earlier risk stratification and more comprehensive preventive strategies across the female lifespan.

PCOS as a Systemic Metabolic Disease

Polycystic ovary syndrome (PCOS) is increasingly conceptualized as a mixed reproductive, metabolic syndrome rather than a purely gynecologic disorder, with implications that extend from adolescence into post‑reproductive life. A substantial body of evidence shows that insulin resistance is a core feature of PCOS, affecting approximately 35–80% of women depending on phenotype and adiposity, and importantly can occur independently of body mass index, indicating an intrinsic defect in insulin signalling. Compensatory hyperinsulinemia exerts pleiotropic endocrine effects: it directly stimulates ovarian theca cells to increase androgen production, augments luteinizing hormone–driven steroidogenesis, and suppresses hepatic synthesis of sex hormone‑binding globulin (SHBG), thereby increasing circulating free androgens and exacerbating clinical hyperandrogenism. This establishes a self‑perpetuating metabolic–reproductive loop in which insulin resistance, hyperinsulinemia, and androgen excess reinforce one another and sustain anovulatory cycles and polycystic ovarian morphology [1,2,3,4,5,6,7,8].

Figure 1. Pathophysiology and neuroendocrine disruption of the hypothalamo-pituitary-gonadal axis in the polycystic ovary syndrome [2]
Figure 1. Pathophysiology and neuroendocrine disruption of the hypothalamo-pituitary-gonadal axis in the polycystic ovary syndrome [2]

Concurrently, many women with PCOS fulfill criteria for metabolic syndrome, characterized by central obesity, elevated triglycerides, reduced HDL‑cholesterol, elevated blood pressure, and impaired glucose regulation. The prevalence of metabolic syndrome is particularly high in obese adolescents and women with PCOS, in whom clustered cardiometabolic risk factors frequently coexist with reproductive symptoms. These metabolic perturbations translate into a higher long‑term risk of type 2 diabetes, with multiple epidemiological studies reporting a two‑ to four‑fold increased incidence of impaired glucose tolerance and diabetes in PCOS compared with weight‑matched controls. In addition, PCOS is associated with increased prevalence of non‑alcoholic fatty liver disease and features of subclinical cardiovascular disease, further supporting its classification as a systemic metabolic disorder with multiorgan involvement. Collectively, this evidence underscores that PCOS should be approached as a chronic cardiometabolic condition with reproductive manifestations, rather than a reproductive disorder with incidental metabolic comorbidities [1,2,3,8,9,10,11,12].

“Diabetes of The Ovaries”: Pathophysiological Rationale

The phrase “diabetes of the ovaries” reflects the centrality of insulin resistance and hyperinsulinemia in PCOS and their convergence with classical diabetic phenotypes. In women with PCOS, metabolically active peripheral tissues such as skeletal muscle and adipose tissue show impaired insulin‑stimulated glucose uptake, driven by defects in post‑receptor signalling, including altered phosphorylation of insulin receptor substrate‑1, Akt, and downstream targets such as AS160. These abnormalities mirror mechanisms described in type 2 diabetes, supporting the concept that PCOS involves a systemic insulin resistance syndrome rather than an isolated ovarian disorder. At the same time, intrinsic, PCOS‑specific signalling defects have been reported, suggesting that insulin resistance in PCOS is not solely explained by obesity or generic type 2 diabetes mechanisms [8,13,14].

A key paradox in PCOS pathophysiology is that, despite systemic insulin resistance, ovarian tissue remains relatively responsive to insulin’s mitogenic and steroidogenic actions. This phenomenon has been framed as “selective insulin resistance,” whereby metabolic pathways mediated largely through the PI3K/Akt axis are impaired, while mitogenic and steroidogenic pathways, often linked to MAPK signalling, remain intact or are even enhanced. In the ovary, insulin acts synergistically with luteinizing hormone (LH) on theca cells to augment expression and activity of steroidogenic enzymes such as CYP17A1, thereby increasing androgen production. Experimental models in which the insulin receptor is deleted specifically in theca cells show attenuation of obesity‑related hyperandrogenism and infertility, confirming a direct, causal role for ovarian insulin signalling in driving androgen excess. In vitro, theca cells from women with PCOS demonstrate heightened androgen responsiveness to physiological insulin concentrations and greater synergistic androgen production in response to combined insulin and LH stimulation than cells from women without PCOS, indicating an intrinsic hyper‑sensitivity of theca cells to insulin [8,15,16,17].

Figure 2. Relationship Between Insulin Resistance and Polycystic Ovary Syndrome (PCOS) [15]

Hyperinsulinemia also exerts systemic endocrine effects that further exacerbate the PCOS phenotype. Insulin suppresses hepatic production of sex hormone‑binding globulin, increasing circulating free androgens and amplifying clinical manifestations such as hirsutism and acne. In parallel, insulin can influence hypothalamic–pituitary function, favouring a higher LH to follicle‑stimulating hormone ratio and contributing to disordered folliculogenesis. Within the ovary, the combination of hyperinsulinemia, elevated LH, and intrinsic theca cell abnormalities leads to excess androgen production, impaired granulosa cell function, and follicular arrest, thereby sustaining chronic anovulation and polycystic ovarian morphology. This “selective insulin resistance” paradigm explains how the ovary behaves as a metabolically sensitive target organ in a body otherwise resistant to insulin’s metabolic actions [4,5,6,8,15,18].

The organ‑specific sensitivity of the ovary to hyperinsulinemia in PCOS conceptually parallels other diabetic complications in which hyperglycemia and hyperinsulinemia drive tissue‑specific pathology against a background of generalized metabolic disturbance. In type 2 diabetes, for example, chronic dysglycemia and altered insulin signalling promote retinopathy, nephropathy, and neuropathy, each reflecting differential vulnerability of local vascular and cellular pathways despite a shared systemic milieu. In PCOS, the ovary may represent an early “end‑organ” of insulin resistance, manifesting with hyperandrogenism and anovulation before overt dysglycemia becomes clinically apparent. Epidemiological data showing increased lifetime risk of impaired glucose tolerance and type 2 diabetes in women with PCOS support the notion that, for a substantial subset of patients, this ovary‑centric insulin resistance syndrome can later progress to classical diabetes. Thus, the metaphor “diabetes of the ovaries” captures both the shared mechanistic foundation of insulin resistance and hyperinsulinemia and the distinctive ovarian sensitivity that converts systemic metabolic dysfunction into a primarily reproductive presentation in early stages of disease [6,8,11,14,15].

Epidemiology of Dysglycemia and Diabetes in PCOS

A substantial epidemiological literature now supports a strong association between PCOS and a spectrum of dysglycemic states, including impaired fasting glucose, impaired glucose tolerance, and type 2 diabetes mellitus (T2DM). Cross‑sectional and prospective studies consistently demonstrate that women with PCOS have markedly higher prevalence of glucose intolerance compared with age‑ and BMI‑matched controls, with estimates from controlled cohorts suggesting impaired glucose tolerance in roughly one‑third and T2DM in up to 10% of affected women in early to mid‑adulthood. In a seminal prospective study of 254 women with PCOS, the prevalence of impaired glucose tolerance and T2DM was significantly higher than in weight‑ and ethnicity‑matched reproductive‑age women, leading the authors to conclude that PCOS itself is an important risk factor for early dysglycemia independent of race or ethnicity. Subsequent meta‑analyses and population‑based cohorts have confirmed that PCOS confers an approximately two‑ to four‑fold increased risk of T2DM across the life course relative to women without PCOS [19,20,21].

Excess adiposity exerts a powerful modifying effect on this risk, with obesity and PCOS acting synergistically to accelerate progression from normoglycemia to overt diabetes. Large registry‑based cohort studies indicate that overweight and obese women with PCOS have substantially higher incidence rates of T2DM than overweight and obese controls, with some analyses reporting several‑fold increases in relative risk, while normal‑weight women with PCOS show either modest or no significant elevation in diabetes risk. Nonetheless, the impact of PCOS is not restricted to older women: long‑term follow‑up studies show that young women diagnosed with PCOS in their twenties and thirties already have an elevated incidence of prediabetes and T2DM, and that relative risks are highest at younger ages compared with age‑matched controls. These findings support calls for proactive glycemic screening, preferably with an oral glucose tolerance test rather than fasting glucose alone, from early adulthood in women with PCOS, particularly when additional risk factors such as obesity, family history of diabetes, or features of metabolic syndrome are present [19,20,21,22,23,24,25].

PCOS is also associated with adverse glycemic trajectories in the context of pregnancy. Several studies report a higher prevalence of gestational diabetes mellitus (GDM) among women with PCOS than among those without the syndrome, reflecting shared underlying insulin resistance and beta‑cell stress. Importantly, women with both PCOS and GDM appear to have a substantially increased risk of persistent glucose metabolism impairment postpartum, with one case–control study demonstrating approximately a 3.5‑fold higher risk of impaired glucose regulation after delivery compared with women with GDM but without PCOS. This combination of PCOS, GDM, and postpartum dysglycemia delineates a particularly high‑risk trajectory for subsequent T2DM and cardiometabolic disease, underscoring the need for intensified postpartum surveillance and long‑term preventive strategies in this subgroup [19,26,27].

Reflecting this body of evidence, major public health and professional organizations now explicitly recognize PCOS as a risk factor for T2DM and recommend regular screening for prediabetes and diabetes in affected women. Guidance from endocrine and diabetes societies, as well as health agencies, emphasizes periodic assessment of fasting glucose and/or oral glucose tolerance, particularly in women with additional risk modifiers such as obesity or previous GDM. From an epidemiological perspective, PCOS thus represents not only a prevalent reproductive disorder but also an important early‑life marker of increased lifetime risk for dysglycemia and T2DM, creating a critical window for targeted metabolic risk assessment and intervention in women of reproductive age [19,21,22].

Beyond Diabetes: Cardiovascular and Multiorgan Risk

The metabolic derangements observed in polycystic ovary syndrome (PCOS) extend beyond abnormalities in glucose homeostasis to encompass a broad constellation of cardiovascular risk factors and target‑organ changes. Women with PCOS display higher rates of hypertension, atherogenic dyslipidemia, central obesity, and clustering of metabolic syndrome components than age‑ and BMI‑matched controls, even at relatively young ages. Typical lipid abnormalities include elevated triglycerides, increased total and LDL‑cholesterol, reduced HDL‑cholesterol, and adverse lipid ratios such as elevated triglyceride‑to‑HDL‑cholesterol and total‑cholesterol‑to‑HDL‑cholesterol indices, often in association with increased waist circumference and elevated blood pressure. In addition, PCOS has been characterized as a state of chronic low‑grade inflammation and pro‑thrombotic tendency, with studies documenting higher levels of inflammatory markers and an overall pro‑inflammatory milieu that is mechanistically linked to atherosclerosis [28, 29,30,31,32].

These risk factor clusters translate into a demonstrable excess burden of clinical cardiovascular disease (CVD) over time. Large cohort studies and meta‑analyses report increased odds or hazard ratios for composite CVD, ischemic heart disease, myocardial infarction, and stroke among women with PCOS compared with controls, even after adjustment for traditional risk factors such as obesity and smoking. An updated meta‑analysis and recent guideline‑linked review found that women with PCOS had approximately two‑fold higher risks of coronary artery disease, heart attack, and stroke, with risk divergence beginning as early as the mid‑thirties in some cohorts. Emerging evidence also points to elevated risks of arrhythmias and heart failure, reinforcing the view that PCOS confers a sustained cardiometabolic burden extending into mid‑life and beyond [29,33,34,35].

Importantly, markers of subclinical vascular injury are already detectable in young women with PCOS, suggesting accelerated vascular aging. Multiple studies have shown increased carotid intima–media thickness (CIMT) in women with PCOS compared with healthy controls, with mean differences of around 0.1–0.2 mm, and CIMT values correlating positively with adverse metabolic profiles. Endothelial dysfunction, assessed by impaired flow‑mediated dilation, has likewise been documented in young PCOS cohorts and is associated with insulin resistance and altered adipokine profiles, including lower adiponectin. These subclinical vascular alterations occur at ages when overt CVD events are rare, underscoring PCOS as a condition of early vascular compromise rather than one that becomes relevant only later in life [28,36,37,38].

Taken together, this body of evidence supports the classification of PCOS as a female‑specific cardiometabolic risk condition, analogous to gestational diabetes and hypertensive disorders of pregnancy as sex‑specific risk enhancers. Expert groups and recent evidence‑based guidelines now highlight PCOS as a “risk‑enhancing” factor for CVD, advocating that cardiologists and preventive clinicians incorporate PCOS history into risk assessment and long‑term monitoring. Framing PCOS in this way emphasizes the need for comprehensive cardiovascular risk stratification and early, multidimensional intervention, targeting blood pressure, lipids, central adiposity, inflammation, and lifestyle, in addition to glycemic control, in order to modify the trajectory of multiorgan cardiometabolic disease in affected women [33,35,39,40].

Heterogeneity: PCOS Phenotypes and Metabolic Risk

Polycystic ovary syndrome (PCOS) is a clinically and biologically heterogeneous disorder, and its metabolic consequences vary substantially across phenotypes defined by combinations of hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. Using the widely adopted Rotterdam and NIH‑based phenotypic schemes, phenotypes A and B (both hyperandrogenic and anovulatory, with phenotype A also having polycystic ovarian morphology) consistently show the most adverse cardiometabolic profiles, including higher prevalence of insulin resistance, dyslipidemia, central adiposity, and metabolic syndrome. Phenotype C (ovulatory but hyperandrogenic with polycystic ovaries) also demonstrates significant metabolic abnormalities, although often to a lesser degree than classic phenotypes A and B. In contrast, phenotype D (oligo‑ovulatory with polycystic ovaries but without hyperandrogenism) usually exhibits the mildest hormonal and metabolic disturbances and, in several cohorts, appears metabolically closer to control women than to hyperandrogenic PCOS phenotypes [41,42,43,44].

Despite these gradations, insulin resistance and related metabolic risk are not restricted to the most “severe” phenotypes. Across diverse populations, insulin resistance is more prevalent and more marked in hyperandrogenic phenotypes, but is still elevated relative to controls in normoandrogenic PCOS, indicating that even phenotypically “mild” presentations can conceal clinically relevant cardiometabolic risk. Several studies show that hyperandrogenism, visceral adiposity, and insulin resistance interact synergistically to drive metabolic syndrome, such that the absence of one factor (for example, hyperandrogenism in phenotype D) attenuates but does not abolish risk. These observations support guideline recommendations to perform cardiometabolic evaluation, including assessment of glucose tolerance, lipids, blood pressure, and central adiposity in all women with PCOS, irrespective of phenotype or body mass index [45,46,47].

Diagnostic criteria themselves also influence the apparent metabolic and cardiovascular burden in PCOS cohorts. Women fulfilling the stricter NIH criteria (requiring both hyperandrogenism and ovulatory dysfunction) generally exhibit more pronounced metabolic abnormalities than those identified only by the broader Rotterdam criteria, which allow inclusion of milder, normoandrogenic phenotypes. Long‑term follow‑up data indicate that women with PCOS, whether defined by NIH or Rotterdam criteria have a significantly higher incidence of major adverse cardiovascular events than control women, with BMI‑adjusted hazard ratios for events such as myocardial infarction and stroke in the range of approximately 2–3; notably, risk appears somewhat higher in NIH‑defined PCOS, consistent with their more adverse metabolic profile. This phenotypic and diagnostic heterogeneity cautions against applying a one‑size‑fits‑all label such as “diabetes of the ovaries” and instead argues for phenotype‑tailored risk stratification, individualized follow‑up intensity, and personalized preventive strategies in women with PCOS [24,41,42,45,47].

Clinical Implications for Screening and Prevention

Viewing polycystic ovary syndrome (PCOS) through a metabolic lens has important implications for how clinicians screen and intervene across the life course. Contemporary international guidelines and expert reviews now recommend that all women with PCOS be systematically assessed for cardiometabolic risk factors, including glycemic status, lipid profile, blood pressure, and central adiposity, regardless of body mass index. The 2023 International Evidence‑Based PCOS Guideline, for example, advises a fasting lipid profile at diagnosis for all women, and endorses the 75‑g oral glucose tolerance test as the most accurate assessment of glycemic status in PCOS, again irrespective of BMI, with repeat testing at defined intervals based on baseline risk. Similar recommendations from endocrine and reproductive societies emphasize regular blood pressure measurement, assessment of waist circumference alongside BMI, and periodic rescreening for type 2 diabetes and metabolic syndrome [45,48,49,50,51,52].

Lifestyle modification remains the cornerstone of PCOS management and the first‑line strategy for both reproductive and metabolic outcomes. Structured interventions combining dietary change and physical activity have been shown to improve insulin sensitivity, reduce fasting insulin levels, promote modest weight loss, and normalize menstrual cyclicity more effectively than either diet or exercise alone. Diets emphasizing reduced refined carbohydrate intake, lower glycemic load, higher fiber, and anti‑inflammatory patterns such as Mediterranean‑style eating can enhance insulin sensitivity and improve cardiometabolic markers in women with PCOS. Regular aerobic and resistance exercise further improves insulin resistance, reduces visceral adiposity, and favourably influences lipid profile and blood pressure, while also conferring psychological benefits. In this context, lifestyle therapy functions not only as symptom management but as a primary prevention strategy for future type 2 diabetes and cardiovascular disease in PCOS [53,54].

Pharmacologic insulin‑sensitizing therapy, particularly with metformin, is widely used as an adjunct to lifestyle intervention. Metformin has been shown to improve insulin resistance, lower fasting glucose, reduce androgen levels, and restore ovulatory cycles and menstrual regularity in many women with PCOS. Meta‑analytic data suggest that metformin may also exert favourable effects on vascular surrogates, including reductions in carotid intima–media thickness and improvements in flow‑mediated dilation, alongside modest improvements in atherogenic lipid parameters, although results are not entirely consistent across randomized trials. Current guidance generally positions metformin as first‑line pharmacologic therapy for women with PCOS who have impaired glucose tolerance, type 2 diabetes, or prominent features of insulin resistance, while its role in primary cardiovascular prevention and in women without dysglycemia remains an area of active investigation [49,51,55].

For clinicians working in preventive, cardiometabolic, and longevity medicine, PCOS can thus be approached as an early red‑flag condition signalling heightened lifetime risk across metabolic, vascular, and reproductive domains. A diagnosis of PCOS should prompt a comprehensive, longitudinal risk‑modification strategy that integrates lifestyle optimization, cardiometabolic screening, and targeted pharmacotherapy rather than focusing solely on short‑term reproductive goals. Embedding PCOS care within broader cardiovascular risk‑reduction programs, alongside education, shared decision‑making, and attention to mental health offers the potential to alter trajectories of type 2 diabetes, atherosclerotic cardiovascular disease, and reproductive aging in this high‑risk female population [48,49,52,53].

Controversies and Limitations of the “Diabetes of The Ovaries” Metaphor

The metaphor of polycystic ovary syndrome (PCOS) as “diabetes of the ovaries” has intuitive appeal because it foregrounds insulin resistance and cardiometabolic risk, but it also represents a substantial oversimplification of a complex and heterogeneous condition. Recent Mendelian randomization (MR) studies and large longitudinal analyses have challenged the notion that PCOS itself is a direct causal driver of type 2 diabetes and atherosclerotic cardiovascular disease, suggesting instead that shared determinants, most notably obesity and related metabolic traits may underlie the observed associations. In sex‑specific MR work, genetically predicted PCOS was not associated with increased risk of coronary artery disease, whereas genetically predicted higher body mass index (BMI) increased risk of both PCOS and coronary artery disease, supporting obesity as a common upstream pathway rather than PCOS per se as a causal factor. Similar MR analyses indicate that PCOS is unlikely to be a causal risk factor for type 2 diabetes, coronary heart disease, or stroke, again pointing to adiposity and hyperinsulinemia as key confounders driving much of the cardiometabolic signal in observational studies [35,56,57,58,59].

These findings highlight a first limitation of the “diabetes of the ovaries” metaphor: it can blur the distinction between correlation and causation and imply an inevitability of diabetes and cardiovascular disease that is not supported for all women with PCOS, particularly those who are lean or have milder phenotypes. Labelling PCOS as intrinsic “diabetes” risks pathologizing all affected women as de facto pre‑diabetic, with potential consequences for stigma, self‑perception, and mental health, especially in lean PCOS phenotypes whose absolute risk of type 2 diabetes may be only modestly increased or uncertain. Qualitative work and clinical experience suggest that framing PCOS primarily as a metabolic or pre‑diabetic state can increase anxiety, fatalism, and confusion about prognosis, particularly when the message is not balanced by discussion of modifiable risk factors and heterogeneity. This is especially salient given that lean women with PCOS, although they can exhibit insulin resistance and subtle metabolic abnormalities, represent a diverse group in whom long‑term diabetes risk remains debated and appears strongly influenced by hyperandrogenic phenotype, ethnicity, and aging [59,60,61].

A second limitation is that the metaphor reduces PCOS to insulin resistance, neglecting the broader neuroendocrine, ovarian, and environmental interactions that characterize the syndrome. PCOS pathophysiology involves altered gonadotropin secretion, intrinsic ovarian theca and granulosa cell dysfunction, adipose tissue and adipokine abnormalities, genetic susceptibility, and developmental and lifestyle factors, many of which are only partly mediated by insulin resistance. MR evidence indicates that childhood and adolescent adiposity, fasting insulin, and low sex hormone–binding globulin each contribute causally to PCOS risk, underscoring that metabolic factors shape, but do not fully explain the reproductive and androgenic features of the disorder. Moreover, not all PCOS‑related complications follow a “diabetic” pattern; for example, reproductive, psychological, and sleep‑related manifestations may have distinct mechanistic pathways and therapeutic targets that are not captured by a diabetes‑centric framing [35,58,60,62].

In light of these considerations, clinicians should deploy the “diabetes of the ovaries” phrase, if at all, as a carefully contextualized communication tool rather than a literal diagnostic label. Used judiciously, it can help convey to some patients that PCOS is a systemic condition with important metabolic implications and that early lifestyle and cardiometabolic interventions are worthwhile. However, counselling should explicitly emphasize individual risk variation by phenotype, BMI, family history, and ethnicity; clarify that PCOS is a risk‑enhancing condition rather than a guarantee of diabetes or cardiovascular disease; and highlight the central role of modifiable factors such as weight, physical activity, diet, and smoking. Framing PCOS as a heterogeneous, multifactorial syndrome with both reproductive and metabolic dimensions, rather than as “ovarian diabetes” per se, may strike a more accurate balance between raising awareness of cardiometabolic risk and avoiding deterministic or stigmatizing messages, particularly in lean and younger women [35,56,59,60,63].

Future Directions in a Precision-Medicine Era

Emerging work in a precision‑medicine era is increasingly focused on disentangling the diverse biological pathways that drive PCOS in order to stratify metabolic risk and tailor therapy more accurately. Research into inositol signalling pathways, tissue‑specific androgen receptor action (particularly in adipose tissue), and granular defects in intracellular insulin signalling is opening the door to more targeted interventions than broad insulin sensitizers alone, including rational use of inositol isomers and combinations of metabolic agents. Parallel efforts aim to build phenotype‑specific and poly‑omic risk tools that incorporate clinical phenotype, genomics, metabolomics, and even gut microbiome signatures to predict which women are most likely to progress to type 2 diabetes, steatotic liver disease, or overt cardiovascular disease, and over what time frame. There is also growing recognition that first‑degree relatives of women with PCOS often share elements of the same metabolic vulnerability, supporting a family‑based perspective on screening and early intervention rather than focusing solely on the index patient. At the health‑systems level, these insights position PCOS as a natural entry point for integrated, life‑course‑oriented care pathways that combine reproductive health management with systematic metabolic screening and cardiovascular prevention in young women.

Conclusion

Polycystic ovary syndrome (PCOS) exemplifies the intersection of reproductive endocrinology and systemic metabolism, with insulin resistance and hyperinsulinemia acting as central drivers of both ovarian dysfunction and long‑term cardiometabolic risk. The clustering of anovulation, hyperandrogenism, dysglycemia, dyslipidemia, and hypertension in women with PCOS has led many investigators to regard the syndrome as an early, sex‑specific manifestation of broader metabolic and cardiovascular vulnerability. In this context, the metaphor of PCOS as “diabetes of the ovaries” captures the concept of the ovary as an early target organ of systemic insulin resistance, where hyperinsulinemia and androgen excess manifest clinically long before overt type 2 diabetes or cardiovascular disease emerge.

However, this metaphor requires careful use. PCOS is a heterogeneous condition encompassing multiple phenotypes with variable degrees of hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology, each associated with distinct metabolic risk profiles. Hyperandrogenic and “classic” phenotypes show the most adverse metabolic profiles, whereas some normoandrogenic phenotypes display more modest risk, underscoring that PCOS is not synonymous with inevitable diabetes or cardiovascular disease. Overgeneralizing the “diabetes of the ovaries” concept risks overstating individual risk, increasing stigma, and obscuring important differences in cardiometabolic vulnerability within the PCOS spectrum.

From a preventive and longevity‑focused standpoint, PCOS should instead be understood as a strategic early‑life window to identify and modify future cardiometabolic risk. Longitudinal data indicate that women with PCOS have higher incidence of type 2 diabetes, hypertension, dyslipidemia, and clinical cardiovascular events across the lifespan, especially when additional risk enhancers such as obesity, metabolic dysfunction–associated steatotic liver disease, or adverse pregnancy outcomes coexist. For clinicians working in wellness, aging, and metabolic health, this reframing supports early, individualized interventions that integrate nutritional, exercise, weight‑management, and, when appropriate, pharmacologic strategies to address both reproductive and cardiometabolic dimensions of PCOS. Such a life‑course approach offers the potential not only to improve fertility and symptom burden in the short term, but also to favourably alter long‑term trajectories of diabetes and cardiovascular disease in women with PCOS

Reference

  1. Amisi CA. Markers of insulin resistance in Polycystic ovary syndrome women: An update. World Journal of Diabetes [Internet]. 2022 Mar 15;13(3):129–49. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC8984569/
  2. Dong J, Rees DA. Polycystic ovary syndrome: Pathophysiology and therapeutic opportunities. BMJ Medicine [Internet]. 2023 Oct 1;2(1). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583117/
  3. Prosperi S, Chiarelli F. Insulin resistance, metabolic syndrome and polycystic ovaries: an intriguing conundrum. Frontiers in Endocrinology. 2025 Oct 1;16.
  4. Baptiste CG, Battista MC, Trottier A, Baillargeon JP. Insulin and hyperandrogenism in women with polycystic ovary syndrome. The Journal of Steroid Biochemistry and Molecular Biology [Internet]. 2010 Oct;122(1-3):42–52. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0960076009003033
  5. Malini N. Influence of Insulin on LH, Testosterone and SHBG in Various PCOS Categories Based on the Mode of Secretion of LH in Relation to FSH Levels. Acta Endocrinologica (Bucharest). 2021;17(3):313–8.
  6. Rojas J, Chávez M, Olivar L, Rojas M, Morillo J, Mejías J, et al. Polycystic Ovary Syndrome, Insulin Resistance, and Obesity: Navigating the Pathophysiologic Labyrinth. International Journal of Reproductive Medicine [Internet]. 2014;2014:1–17. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334071/
  7. Ding H, Zhang J, Zhang F, Zhang S, Chen X, Liang W, et al. Resistance to the Insulin and Elevated Level of Androgen: A Major Cause of Polycystic Ovary Syndrome. Frontiers in Endocrinology. 2021 Oct 20;12.
  8. Purwar A, Nagpure S. Insulin resistance in polycystic ovarian syndrome. Cureus [Internet]. 2022 Oct 16;14(10). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665922/
  9. Kumarendran B, O’Reilly MW, Manolopoulos KN, Toulis KA, Gokhale KM, Sitch AJ, et al. Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a United Kingdom primary care database. Myers JE, editor. PLOS Medicine. 2018 Mar 28;15(3):e1002542.
  10. Vassilatou E. Nonalcoholic fatty liver disease and polycystic ovary syndrome. World Journal of Gastroenterology. 2014;20(26):8351.
  11. Marshall JC, Dunaif A. Should all women with PCOS be treated for insulin resistance? Fertility and Sterility [Internet]. 2012 Jan;97(1):18–22. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3277302/
  12. Dawson AJ, Sathyapalan T, Smithson JAJ, Vince RV, Coady AM, Ajjan R, et al. A comparison of cardiovascular risk indices in patients with polycystic ovary syndrome with and without coexisting nonalcoholic fatty liver disease. Clinical endocrinology [Internet]. 2014 Jun;80(6):843–9. Available from: https://pubmed.ncbi.nlm.nih.gov/23746214/
  13. Corbould A. Insulin resistance in skeletal muscle and adipose tissue in polycystic ovary syndrome: are the molecular mechanisms distinct from type 2 diabetes? Panminerva medica [Internet]. 2008 Dec;50(4):279–94. Available from: https://pubmed.ncbi.nlm.nih.gov/19078869/
  14. Stepto NK, Hiam D, Gibson-Helm M, Cassar S, Harrison CL, Hutchison SK, et al. Exercise and insulin resistance in PCOS: muscle insulin signalling and fibrosis. Endocrine Connections [Internet]. 2020 Apr;9(4):346–59. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7219141/pdf/EC-19-0551.pdf
  15. Chen X, Wan Y, Xie L. Insulin Resistance in PCOS: Pathophysiological Mechanisms of Menstrual Dysfunction and Evidence-Based Treatment Strategies. Biology of reproduction [Internet]. 2025;ioaf197. Available from: https://pubmed.ncbi.nlm.nih.gov/40883896/
  16. Cadagan D, Khan R, Amer S. Thecal cell sensitivity to luteinizing hormone and insulin in polycystic ovarian syndrome. Reproductive Biology [Internet]. 2016 Mar;16(1):53–60. Available from: https://www.sciencedirect.com/science/article/pii/S1642431X16000036
  17. Wu S, Divall S, Nwaopara A, Radovick S, Wondisford F, Ko C, et al. Obesity-Induced Infertility and Hyperandrogenism Are Corrected by Deletion of the Insulin Receptor in the Ovarian Theca Cell. Diabetes [Internet]. 2014 Apr 1;63(4):1270–82. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3964497/
  18. Wu XK, Zhou SY, Liu JX, Pöllänen P, Sallinen K, Mäkinen M, et al. Selective ovary resistance to insulin signaling in women with polycystic ovary syndrome. Fertility and Sterility. 2003 Oct;80(4):954–65.
  19. Livadas S, Anagnostis P, Bosdou JK, Bantouna D, Paparodis R. Polycystic ovary syndrome and type 2 diabetes mellitus: A state-of-the-art review. World Journal of Diabetes [Internet]. 2022 Jan 15;13(1):5–26. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771268/
  20. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and Predictors of Risk for Type 2 Diabetes Mellitus and Impaired Glucose Tolerance in Polycystic Ovary Syndrome: A Prospective, Controlled Study in 254 Affected Women1. The Journal of Clinical Endocrinology & Metabolism. 1999 Jan;84(1):165–9.
  21. Gambineri A, Patton L, Altieri P, Pagotto U, Pizzi C, Manzoli L, et al. Polycystic Ovary Syndrome Is a Risk Factor for Type 2 Diabetes: Results From a Long-Term Prospective Study. Diabetes [Internet]. 2012 Jun 14;61(9):2369–74. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425413/
  22. Liao WT, Huang JY, Lee MT, Yang YC, Wu CC. Higher risk of type 2 diabetes in young women with polycystic ovary syndrome: A 10-year retrospective cohort study. World Journal of Diabetes [Internet]. 2022 Mar 15;13(3):240–50. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984565/
  23. Anagnostis P, Paparodis R, Bosdou J, Bothou C, Goulis DG, Macut DP, et al. The Major Impact of Obesity on the Development of Type 2 Diabetes (T2D) in Women With PCOS: A Systematic Review and Meta-Analysis of Observational Studies. Journal of the Endocrine Society. 2021 May 1;5(Supplement_1):A746–7.
  24. Ollila MM .E., West S, Keinänen-Kiukaanniemi S, Jokelainen J, Auvinen J, Puukka K, et al. Overweight and obese but not normal weight women with PCOS are at increased risk of Type 2 diabetes mellitus—a prospective, population-based cohort study. Human Reproduction. 2016 Dec 28;32(2):423–31.
  25. Kakoly NS, Earnest A, Teede HJ, Moran LJ, Joham AE. The Impact of Obesity on the Incidence of Type 2 Diabetes Among Women With Polycystic Ovary Syndrome. Diabetes Care [Internet]. 2019 Jan 31 [cited 2020 Jan 28];42(4):560–7. Available from: https://care.diabetesjournals.org/content/42/4/560
  26. Palomba S, Falbo A, Russo T, Rivoli L, Orio M, Cosco AG, et al. The Risk of a Persistent Glucose Metabolism Impairment After Gestational Diabetes Mellitus Is Increased in Patients With Polycystic Ovary Syndrome. Diabetes Care. 2012 Feb 14;35(4):861–7.
  27. Fatemeh Foroozanfard, Abbas G, Mansouri F, Fatemeh Bazarganipour. Obstetric and Neonatal Outcome in PCOS with Gestational Diabetes Mellitus. Journal of Family & Reproductive Health [Internet]. 2014 Mar;8(1):7. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC4064757/
  28. Scicchitano P, Dentamaro I, Carbonara R, Bulzis G, Dachille A, Caputo P, et al. Cardiovascular Risk in Women With PCOS. International Journal of Endocrinology and Metabolism [Internet]. 2012 Sep 30;10(4):611–8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3693634/
  29. Badejogbin OC, Agunloye MO, Chijioke-Agu OE, Olubiyi MV, Olugbuyiro SO, Soetan OA, et al. Cardiovascular Dysfunction in Polycystic Ovary Syndrome: Mitochondrial and Inflammatory Mechanisms. Flora SJS, editor. BioMed Research International [Internet]. 2026 Jan;2026(1). Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12835629/
  30. Djuro Macut, Bačević M, Božić-Antić I, Jelica Bjekić-Macut, Milorad Čivčić, Erceg S, et al. Predictors of Subclinical Cardiovascular Disease in Women with Polycystic Ovary Syndrome: Interrelationship of Dyslipidemia and Arterial Blood Pressure. International journal of endocrinology. 2015 Jan 1;2015:1–9.
  31. Yulith Roca Alvarez, Pico M, Namrita Ashokprabhu, Abou-Amro K, Bailey S, Pung E, et al. Polycystic Ovarian Syndrome: a Risk Factor for Cardiovascular Disease. Current atherosclerosis reports. 2023 Dec 1;25(12):1003–11.
  32. Pradhan J, Mishra I, Rattan R, Choudhury AK, Baliarsinha AK. Correlation of Markers of Inflammation with Hormonal, Metabolic Parameters, Insulin Resistance and Adiposity Indices in First-Degree Relatives of Patient with Polycystic Ovary Syndrome. Journal of Human Reproductive Sciences [Internet]. 2022 Jul [cited 2026 Feb 12];15(3):250–8. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9635376/
  33. Chau Thien Tay, Mousa A, Vyas A, Loyal Pattuwage, Fahimeh Ramezani Tehrani, Teede H. 2023 International Evidence‐Based Polycystic Ovary Syndrome Guideline Update: Insights From a Systematic Review and Meta‐Analysis on Elevated Clinical Cardiovascular Disease in Polycystic Ovary Syndrome. Journal of the American Heart Association. 2024 Aug 9;13(16).
  34. Ollila MM, Arffman RK, Korhonen E, L Morin-Papunen, Franks S, M Juhani Junttila, et al. Women with PCOS have an increased risk for cardiovascular disease regardless of diagnostic criteria – a prospective population-based cohort study. European Journal of Endocrinology. 2023 Jul 12;189(1).
  35. Geraci G, Riccio C, Oliva F, Gabrielli D, Furio Colivicchi, Grimaldi M, et al. Women with PCOS have a heightened risk of cardiometabolic and cardiovascular diseases: statement from the Experts Group on Inositol in Basic and Clinical Research and PCOS (EGOI-PCOS) and Italian Association of Hospital Cardiologists (ANMCO). Frontiers in Cardiovascular Medicine. 2025 Sep 2;12.
  36. Jabbour R, Ott J, Eppel W, Frigo P. Carotid intima-media thickness in polycystic ovary syndrome and its association with hormone and lipid profiles. Laganà AS, editor. PLOS ONE. 2020 Apr 24;15(4):e0232299.
  37. Carmina E, Orio F, Palomba S, Longo RA, Cascella T, Colao A, et al. Endothelial Dysfunction in PCOS: Role of Obesity and Adipose Hormones. The American Journal of Medicine. 2006 Apr;119(4):356.e1–6.
  38. Farshchian N, Kamangar PB, Ghasempour MR. Carotid artery intima-media thickness in women with polycystic ovary syndrome: A cross-sectional study. International Journal of Reproductive BioMedicine (IJRM) [Internet]. 2024 Nov 10 [cited 2026 Feb 12];22(9):749–54. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11602738/
  39. Sotirios Pililis, Stamatios Lampsas, Aikaterini Kountouri, Loukia Pliouta, Emmanouil Korakas, Sarantis Livadas, et al. The Cardiometabolic Risk in Women with Polycystic Ovarian Syndrome (PCOS): From Pathophysiology to Diagnosis and Treatment. Medicina. 2024 Oct 10;60(10):1656–6.
  40. Guan C, Zahid S, Minhas AS, Ouyang P, Vaught A, Baker VL, et al. Polycystic ovary syndrome: a “risk-enhancing” factor for cardiovascular disease. Fertility and Sterility [Internet]. 2022 May 1;117(5):924–35. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0015028222001935
  41. Ma YC, Law KS, Wang WS, Chang HM. Phenotypic variations in polycystic ovary syndrome: metabolic risks and emerging biomarkers. Journal of Endocrinology. 2025 Sep 19;267(1).
  42. Gluszak O, Stopinska-Gluszak U, Glinicki P, Kapuscinska R, Snochowska H, Zgliczynski W, et al. Phenotype and Metabolic Disorders in Polycystic Ovary Syndrome. ISRN Endocrinology. 2012 Feb 29;2012:1–7.
  43. Sobti S, Dewan R, Ranga S. Metabolic syndrome and insulin resistance in PCOS phenotypes. International Journal of Reproduction, Contraception, Obstetrics and Gynecology. 2017 Oct 28;6(11):5067.
  44. Leili Rahmatnezhad, Moghaddam-Banaem L, Tahereh Behroozi-Lak, Shiva A, Javad Rasouli. Association of insulin resistance with polycystic ovary syndrome phenotypes and patients’ characteristics: a cross-sectional study in Iran. Reproductive Biology and Endocrinology. 2023 Nov 25;21(1).
  45. Krentowska A, Kowalska I. Metabolic syndrome and its components in different phenotypes of polycystic ovary syndrome. Diabetes/Metabolism Research and Reviews. 2021 May 14;
  46. Wen X, Wang L, Bai E. Metabolic characteristics of different phenotypes in reproductive-aged women with polycystic ovary syndrome. Frontiers in Endocrinology. 2024 Jul 23;15.
  47. Piotr Szkodziak, Sławomir Woźniak. Insulin resistance in polycystic ovary syndrome phenotypes and the vicious cycle model in its etiology. Scientific Reports. 2025 Nov 28;15(1):42649–9.
  48. Maidarti M, Harzif AK, Shadrina A, Ummah N, Permadi W. Executive summary: Indonesian guidelines on polycystic ovary syndrome management. Obstetrics & Gynecology Science. 2025 Mar 26;
  49. Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology and Metabolism [Internet]. 2023;108(10):2447–69. Available from: https://pubmed.ncbi.nlm.nih.gov/37580314/
  50. International evidence-based guideline for the assessment and management of polycystic ovary syndrome – 2023. REPRODUCTIVE ENDOCRINOLOGY [Internet]. 2023 Sep 29;(69):59–79. Available from: https://www.monash.edu/__data/assets/pdf_file/0003/3371133/PCOS-Guideline-Summary-2023.pdf
  51. Williams T, Mortada R, Porter S. Diagnosis and Treatment of Polycystic Ovary Syndrome. American Family Physician [Internet]. 2016 Jul 15;94(2):106–13. Available from: https://www.aafp.org/pubs/afp/issues/2016/0715/p106.html
  52. Long-term Consequences of Polycystic Ovary Syndrome Green-top Guideline No. 33 [Internet]. 2014. Available from: https://www.rcog.org.uk/media/qmtlp2b0/gtg_33.pdf
  53. Gautam R, Maan P, Jyoti A, Kumar A, Malhotra N, Arora T. The Role of Lifestyle Interventions in PCOS Management: A Systematic Review. Nutrients [Internet]. 2025 Jan 16;17(2):310–0. Available from: https://www.mdpi.com/2072-6643/17/2/310
  54. Kim CH, Lee SH. Effectiveness of Lifestyle Modification in Polycystic Ovary Syndrome Patients with Obesity: A Systematic Review and Meta-Analysis. Life. 2022 Feb 18;12(2):308.
  55. Wang F, Yan Y, Wang D, Fan Q, Yi F, Yang X, et al. Effects of Metformin on CIMT and FMD in PCOS patients: a systematic review and meta-analysis. BMC Women’s Health [Internet]. 2024 Jul 26;24(1):1–11. Available from: https://search.ebscohost.com/login.aspx?direct=true&AuthType=shib&db=cul&AN=178621871&site=ehost-live&custid=ns251549
  56. Zhu T, Goodarzi MO. SUN-016 Mendelian Randomization Reveals That Polycystic Ovary Syndrome Is Not a Causal Risk Factor for Type 2 Diabetes, Coronary Heart Disease, or Stroke. Journal of the Endocrine Society. 2020 Apr;4(Supplement_1).
  57. Simons G, Merel, Valkenburg O, N. Charlotte Onland-Moret, Yvonne, Coen D.A. Stehouwer, et al. Causal relationship between polycystic ovary syndrome and coronary artery disease: A Mendelian randomisation study. Clinical Endocrinology. 2021 Sep 15;96(4):599–604.
  58. Dobbie LJ, Pittam B, Sizheng Steven Zhao, Alam U, Hydes TJ, Barber TM, et al. Childhood, adolescent, and adulthood adiposity are associated with risk of PCOS: a Mendelian randomization study with meta-analysis. 2023 Apr 4;
  59. Guan C, Zahid S, Minhas AS, Ouyang P, Vaught A, Baker VL, et al. Polycystic ovary syndrome: a “risk-enhancing” factor for cardiovascular disease. Fertility and Sterility [Internet]. 2022 May 1 [cited 2022 Dec 3];117(5):924–35. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0015028222001935
  60. Henney AE, Gillespiec CS, Lai JYM, Schofield P, Riley DR, Caleyachetty R, et al. Risk of Type 2 Diabetes, MASLD and Cardiovascular Disease in People Living With Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology & Metabolism. 2024 Jul 11;
  61. Dawood A, Goyal M. Debates regarding lean patients with polycystic ovary syndrome: A narrative review. Journal of Human Reproductive Sciences. 2017;10(3):154.
  62. Zhang C, Li Y, Wang Y, Hu S, Liu Y, Liang X, et al. Genetic associations of metabolic factors and therapeutic drug targets with polycystic ovary syndrome. Journal of Advanced Research [Internet]. 2024 Nov 1; Available from: https://www.sciencedirect.com/science/article/pii/S2090123224004922
  63. Glintborg D, Kolster ND, Ravn P, Andersen MS. Prospective Risk of Type 2 Diabetes in Normal Weight Women with Polycystic Ovary Syndrome. Biomedicines. 2022 Jun 20;10(6):1455.

‌

Discover more from A1C Almanac

Subscribe now to keep reading and get access to the full archive.

Continue reading